Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Martin, M; Brase, JC; Ruiz, A; Prat, A; Kronenwett, R; Calvo, L; Petry, C; Bernard, PS; Ruiz-Borrego, M; Weber, KE; Rodriguez, CA; Alvarez, IM; Segui, MA; Perou, CM; Casas, M; Carrasco, E; Caballero, R; Rodriguez-Lescure, A.

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

BREAST CANCER RESEARCH AND TREATMENT. 2016; 156(1): 81-89 Nº de citas: 45 [doi:10.1007/s10549-016-3725-z]

Reynes, G; Martinez-Sales, V; Vila, V; Balana, C; Perez-Segura, P; Vaz, MA; Benavides, M; Gallego, O; Palomero, I; Gil-Gil, M; Fleitas, T; Reche, E.

Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma

ANTI-CANCER DRUGS. 2016; 27(2): 133-137 Nº de citas: 11 [doi:10.1097/CAD.0000000000000314]

Masson-Lecomte, A; de Maturana, EL; Goddard, ME; Picornell, A; Rava, M; Gonzalez-Neira, A; Marquez, M; Carrato, A; Tardon, A; Lloreta, J; Garcia-Closas, M; Silverman, D; Rothman, N; Kogevinas, M; Allory, Y; Chanock, SJ; Real, FX; Malats, N; SBC EPICURO Study Investigators.

Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment

CANCER EPIDEM BIOMAR. 2016; 25(7): 1144-1150 Nº de citas: 3 [doi:10.1158/1055-9965.EPI-15-0894]

De las Penas, R; Ponce, S; Henao, F; Herrero, CC; Carcereny, E; Alvarez, YE; Rodriguez, CA; Virizuela, JA; Lopez, RL.

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan

SUPPORTIVE CARE IN CANCER. 2016; 24(1): 499-507 Nº de citas: 11 [doi:10.1007/s00520-015-2948-6]

Stopeck, AT; Fizazi, K; Body, JJ; Brown, JE; Carducci, M; Diel, I; Fujiwara, Y; Martin, M; Paterson, A; Tonkin, K; Shore, N; Sieber, P; Kueppers, F; Karsh, L; Yardley, D; Wang, H; Maniar, T; Arellano, J; Braun, A.

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

SUPPORTIVE CARE IN CANCER. 2016; 24(1): 447-455 Nº de citas: 146 [doi:10.1007/s00520-015-2904-5]

Lipton, A; Fizazi, K; Stopeck, AT; Henry, DH; Smith, MR; Shore, N; Martin, M; Vadhan-Raj, S; Brown, JE; Richardson, GE; Saad, F; Yardley, DA; Zhou, K; Balakumaran, A; Braun, A.

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

EUROPEAN JOURNAL OF CANCER. 2016; 53: 75-83 Nº de citas: 94 [doi:10.1016/j.ejca.2015.09.011]

Martinez, MT; Perez-Fidalgo, JA; Martin-Martorell, P; Cejalvo, JM; Pons, V; Bermejo, B; Martin, M; Albanell, J; Lluch, A.

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2016; 97: 96-106 Nº de citas: 48 [doi:10.1016/j.critrevonc.2015.08.011]

Gayarre, J; Kamieniak, MM; Cazorla-Jimenez, A; Munoz-Repeto, I; Borrego, S; Garcia-Donas, J; Hernando, S; Robles-Diaz, L; Garcia-Bueno, JM; Cajal, TRY; Hernandez-Agudo, E; Soto, VH; Marquez-Rodas, I; Echarri, MJ; Lacambra-Calvet, C; Saez, R; Cusido, M; Redondo, A; Paz-Ares, L; Hardisson, D; Mendiola, M; Palacios, J; Benitez, J; Garcia, MJ.

The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients

Journal of Gynecologic Oncology. 2016; 27(1): Nº de citas: 18 [doi:10.3802/jgo.2016.27.e7]

Gonzalez-Martin, A; Alba, E; Ciruelos, E; Cortes, J; Llombart, A; Lluch, A; Andres, R; Alvarez, I; Aramenda, JM; de la Pena, FA; Barnadas, A; Batista, N; Calvo, L; Galve, E; Garcia-Palomo, A; Garcia-Saenz, JA; de la Haba, J; Lopez, R; Lopez-Vivanco, G; Martinez-Janez, N; de Duenas, EM; Plazaola, A; Rodriguez-Lescure, A; Ruiz, M; Sanchez-Rovira, P; Santaballa, A; Segui, MA; Tusquets, I; Zamora, P; Martin, M.

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile

CURRENT CANCER DRUG TARGETS. 2016; 16(5): 415-428 Nº de citas: 11 [doi:10.2174/1568009615666150817121731]

Llovet, P; Sastre, J; Ortega, JS; Bando, I; Ferrer, M; Garcia-Alfonso, P; Donnay, O; Carrato, A; Jimenez, A; Aranda, E; Leon, A; Gravalos, C; Camara, JC; Feliu, J; Sanchiz, B; Caldes, T; Diaz-Rubio, E.

Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy

MOLECULAR DIAGNOSIS & THERAPY. 2015; 19(6): 397-408 Nº de citas: 20 [doi:10.1007/s40291-015-0165-0]

Garcia-Alfonso, P; Ferrer, A; Gil, S; Duenas, R; Perez, MT; Molina, R; Capdevila, J; Safont, MJ; Castanon, C; Cano, JM; Lara, R.

Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents

TARGETED ONCOLOGY. 2015; 10(4): 453-465 Nº de citas: 15 [doi:10.1007/s11523-015-0362-0]

Sole, CV; Calvo, FA; Lizarraga, S; Gonzalez-Bayon, L; Segundo, CGS; Desco, M; Garcia-Sabrido, JL.

Single-Institution Multidisciplinary Management of Locoregional Oligo-Recurrent Pelvic Malignancies: Long-Term Outcome Analysis

ANNALS OF SURGICAL ONCOLOGY. 2015; 22: 1247-1255 Nº de citas: 4 [doi:10.1245/s10434-015-4604-2]

Berrocal, A; Arance, A; Espinosa, E; Castano, AG; Cao, MG; Larriba, JLG; Martin, JAL; Marquez, I; Soria, A; Algarra, SM.

SEOM guidelines for the management of Malignant Melanoma 2015

CLINICAL & TRANSLATIONAL ONCOLOGY. 2015; 17(12): 1030-1035 Nº de citas: 6 [doi:10.1007/s12094-015-1450-4]

Aranda, E; Aparicio, J; Alonso, V; Garcia-Albeniz, X; Garcia-Alfonso, P; Salazar, R; Valladares, M; Vera, R; Vieitez, JM; Garcia-Carbonero, R.

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

CLINICAL & TRANSLATIONAL ONCOLOGY. 2015; 17(12): 972-981 Nº de citas: 27 [doi:10.1007/s12094-015-1434-4]

Gavila, J; Lopez-Tarruella, S; Saura, C; Munoz, M; Oliveira, M; De la Cruz-Merino, L; Morales, S; Alvarez, I; Virizuela, JA; Martin, M.

SEOM clinical guidelines in metastatic breast cancer 2015

CLINICAL & TRANSLATIONAL ONCOLOGY. 2015; 17(12): 946-955 Nº de citas: 23 [doi:10.1007/s12094-015-1476-7]

Martin, M; Simon, AR; Borrego, MR; Ribelles, N; Rodriguez-Lescure, A; Munoz-Mateu, M; Gonzalez, S; Vila, MM; Barnadas, A; Ramos, M; Berron, SD; Jara, C; Calvo, L; Martinez-Janez, N; Fernandez, CM; Rodriguez, CA; de Duenas, EM; Andres, R; Plazaola, A; de la Haba-Rodriguez, J; Lopez-Vega, JM; Adrover, E; Ballesteros, AI; Santaballa, A; Sanchez-Rovira, P; Baena-Canada, JM; Casas, M; Camara, MD; Carrasco, EM; Lluch, A.

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(32): 3788 Nº de citas: 59 [doi:10.1200/JCO.2015.61.9510]

Sole, CV; Calvo, FA; Lizarraga, S; Gonzalez-Bayon, L; Garcia-Sabrido, JL.

Intraoperative electron-beam radiation therapy with or without external-beam radiotherapy in the management of paraaortic lymph-node oligometastases from gynecological malignancies

CLINICAL & TRANSLATIONAL ONCOLOGY. 2015; 17(11): 910-916 Nº de citas: 6 [doi:10.1007/s12094-015-1326-7]

Climent, MA; Leon-Mateos, L; del Alba, AG; Perez-Valderrama, B; Mendez-Vidal, MJ; Mellado, B; Arranz, JA; Sanchez-Hernandez, A; Cassinello, J; Olmos, D; Carles, J.

Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2015; 96(2): 308-318 Nº de citas: 14 [doi:10.1016/j.critrevonc.2015.05.019]